Introduction
The oncogenic role of the c-Jun transcription factor has been shown in various cell systems and mouse models (Eferl and Wagner, 2003) . c-Jun/AP-1 target genes control multiple hallmarks of cancer by encoding key regulators of cell-cycle progression, apoptosis, tumor cell invasiveness and angiogenesis (Eferl and Wagner, 2003; Ozanne et al., 2007) . Despite recent evidence of JUN gene amplification in sarcomas (Mariani et al., 2007) , the oncogenic activity of c-Jun in most tumors results mainly from overexpression and/or posttranslational modifications of the protein (Eferl and Wagner, 2003) .
Heterodimerization is a key regulatory mechanism of AP-1 activity (Chinenov and Kerppola, 2001; Vinson et al., 2002) . In addition to increasing the affinity for DNA of Jun/Fos heterodimers vs Jun/Jun homodimers, cross-family heterodimerization controls the DNAbinding specificity of AP-1 complexes. c-Jun can also control posttranslational modifications, stability and subcellular localization of its heterodimeric partners, such as c-Fos, JunD and ATF2 (activating transcription factor-2). c-Jun can target c-Fos for degradation, by mechanisms affected by TPA-induced phosphorylation of c-Jun (Papavassiliou et al., 1992) . Similarly, c-Jun can destabilize ATF2 by promoting ATF2 ubiquitylation and proteasomal degradation (Fuchs and Ronai, 1999) . In addition, c-Jun recruits Jun N-terminal kinase (JNK) to phosphorylate JunD, which harbors the JNK phosphoacceptor residues but lacks its own JNK docking site (Kallunki et al., 1996) . It also prevents ATF2 nuclear export in response to stress-mediated activation of the JNK pathway (Liu et al., 2006) and inhibits the nucleo-cytoplasmic shuttling (Malnou et al., 2007) and intracellular mobility (Malnou et al., 2010) of c-Fos. At variance with the multiple effects of c-Jun on its heterodimeric partners, little is known about the influence of Fos family proteins on c-Jun accumulation and activity.
Several transduction pathways have been implicated in the control of c-Jun protein turnover. JNK-dependent phosphorylation can either accelerate or slow down c-Jun breakdown, depending on the conditions. JNKmediated phosphorylation of multiple c-Jun residues (S63/S73/T91/T93) can inhibit c-Jun polyubiquitylation and subsequent proteasomal degradation in response to upstream activators of the JNK pathway (Fuchs et al., 1996; Musti et al., 1997) . However, JNK family mitogen-activated protein kinases can also accelerate rather than inhibit c-Jun turnover, depending on the specific JNK isoform and cell context. In fibroblasts, JNK1 is a positive regulator of c-Jun phosphorylation and stability, whereas interaction with JNK2 accelerates c-Jun breakdown (Sabapathy et al., 2004) . During T-cell activation, c-Jun degradation results from c-Jun ubiquitylation by the E3 ligase Itch, which is activated by JNK-mediated phosphorylation (Gao et al., 2004) . In neurons, the increased c-Jun turnover triggered by proapoptotic activity of the JNKs is mediated by direct phosphorylation of c-Jun S63, S73, T91 and T93 residues, which permits recruitment of the E3 ubiquitin ligase SCF Fbw7 and subsequent degradation (Nateri et al., 2004) . Finally, in other cell contexts, JNK phosphoacceptor sites do not affect c-Jun stability. Instead, glycogen synthase kinase-3 (GSK3)-mediated phosphorylation of a c-Jun COOH-proximal residue (Thr239), primed by phosphorylation of Ser243, is essential for c-Jun recognition and ubiquitylation by SCF Fbw7 , following a mechanism similar to that responsible for proteasomal degradation of c-Myc and cyclin E. As a result, during cell-cycle progression, Aktmediated inhibitory phosphorylation of GSK3 allows dephosphorylation of c-Jun at Thr239 and transient inhibition of c-Jun degradation in response to activation of the RTK/RAS/phosphoinositide 3-kinase/Akt/GSK3 pathway (Wei et al., 2005) .
Among the c-Jun heterodimeric partners induced by neoplastic transformation, Fra-1 is the most abundant Fos family member in multiple in vitro transformed cell lines and in tumors expressing the RAS oncoprotein (Verde et al., 2007) . Fra-1 accumulation results from transcriptional autoregulation of the Fra-1 gene (fosl1), along with posttranslational stabilization of the protein in response to the RAF/MEK/extracellular signalrelated kinase (ERK) pathway (Casalino et al., 2003; Vial et al., 2003; Basbous et al., 2007) . Fra-1 decay is mediated by a C-terminal destabilizer, which is inhibited by ERK phosphorylation of two serine residues (S252 and S265) responsible for Fra-1 stabilization in certain tumor cell lines showing constitutive mitogen-activated protein kinase activity (Basbous et al., 2007) .
In rat thyroid cell lines expressing the retroviral Ki-RAS or an inducible derivative of the H-RASV12 oncoprotein, we have previously shown that Fra-1 accumulates to high levels, along with c-Jun and JunB (Casalino et al., 2003; Talotta et al., 2009) . Surprisingly, differing from Fra-1 and JunB, RAS-induced increase in c-Jun did not reflect significant changes at the transcriptional level (Vallone et al., 1997) . In this study, we have attempted to dissect the mechanism of RAS-mediated upregulation of the c-Jun protein.
Results and Discussion
First, we analyzed the decay rate of c-Jun in both a Ki-RAS-transformed rat thyroid cell line (FRTL-5
Ki-RAS ) vs its normal counterpart ( Figure 1a and Supplementary Figure S1 ) and in an inducible cell system (FRTL-5 ER-RAS ) derived from the FRTL5 rat thyroid cell line wherein an ER-RASV12 fusion protein can be activated by tamoxifen treatment (De Vita et al., 2004) . Quantitation of immunoprecipitation and immunoblotting data showed that c-Jun half-life more than doubled in a RAS-dependent manner, increasing from B2 h to 45 h in both cell systems (Figure 1b) . In addition, c-Jun stabilization represented a direct response detectable within 24 h of RAS induction in FRTL-5 ER-RAS cells rather than a general indirect consequence of neoplastic transformation. RAS-dependent stabilization seemed to affect c-Jun specifically, as it was not observed for JunB (Supplementary Figure S2) .
Given the previously reported role of polyubiquitylation in controlling c-Jun degradation (Treier et al., 1994) , we analyzed the effect of RAS on the in vivo ubiquitylation of c-Jun, in FRTL-5 vs FRTL-5
Ki-RAS cells. Polyubiquitylated c-Jun, represented by the multiple 455 kDa HA-ubiquitin-conjugated species, was much less abundant in FRTL-5
Ki-RAS than in FRTL-5 cells (Figure 1c ), suggesting that c-Jun stabilization resulted from decreased c-Jun polyubiquitylation in the RAS-transformed cell line.
To investigate the potential role of the JNK and ERK pathways in c-Jun stabilization, we measured c-Jun halflife in Ki-RAS cells treated with selective kinase inhibitors. Although phosphorylation of c-Jun on Ser73 was significantly affected, protein half-life was not affected when Ki-RAS cells were treated with the JNK-specific inhibitor (Figure 1d ). This result suggests that the previously reported mechanisms of JNKmediated stabilization of c-Jun (Fuchs et al., 1996; Musti et al., 1997; Gao et al., 2004; Nateri et al., 2004; Sabapathy et al., 2004) are not implicated in the control of c-Jun turnover in RAS-transformed rat thyroid cells.
Pulse-chase analysis showed that c-Jun half-life was significantly decreased by treatment with the MEK/ ERK pathway-specific inhibitor U0126 (Figure 1d) . Therefore, the MEK/ERK pathway positively controls c-Jun stability in RAS-transformed thyroid cells. The lack of effect of U0126 on c-Jun-Ser73 phosphorylation under conditions not affecting c-Jun level ( Figure 1d ) suggests that phosphorylations of the N-terminal part of this protein are not implicated in ERK-mediated stabilization and raise the question of the possible role of other c-Jun phosphoacceptor sites. It has been reported that ERK inhibition can antagonize TPAinduced dephosphorylation of c-Jun Thr239 (Morton et al., 2003) . GSK3-mediated phosphorylation of Thr239 generates a docking site for Fbw7, which triggers both ubiquitylation and degradation of c-Jun (Wei et al., 2005) .
We have recently shown that AP-1 activity in the RAS-inducible cell line FRTL-5 ER-RAS can be stably inhibited upon expression of a powerful dominantnegative AP-1 construct (GFP (green fluorescent protein)-aFOS) (Bahassi et al., 2004) . GFP-aFOS is an enhanced GFP-based chimeric protein displaying dramatically enhanced c-Fos heterodimerization affinity Ki-RAS rat thyroid lines (cell morphology shown in Supplementary Figure S1 ). Pulse-chase analysis was performed as previously described (Casalino et al., 2003) . After methionine/cysteine starvation, subconfluent cells were labeled with 35S (Pro-Mix; 100 mC in 1 ml; GE-Healthcare, Buckinghamshire, UK) for 1 h, washed and switched in fresh medium for the indicated times. Cell extracts (500 mg) were subjected to immunoprecipitation with 2 mg of anti-c-Jun (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunocomplexes were recovered on protein A-Sepharose beads (GE-Healthcare) and resolved by 10% SDS-PAGE. Ki-RAS cells was followed by affinity purification onto Ni 2 þ -agarose (Treier et al., 1994) and immunoblotting analysis of His-tagged complexes by an anti-HA antibody (Santa Cruz Biotechnology). (d) The ERK pathway stabilizes, whereas the JNK pathway does not affect the cJun half-life in RAS-transformed thyroid cells. Ki-RAS cells were treated with MEK/ERK-or JNK-specific inhibitors (30 mM SP600125 or 10 mM U0126, Merck KGaA, Darmstadt, Germany) for 30 min before pulse-chase labeling. The inhibition of JNK or ERK activity was monitored by immunoblotting, using phospho-specific antibodies (Cell Signaling) recognizing c-Jun (Ser73), c-Jun (Ser73) and the active phosphorylated isoforms of ERK1/2 and JNK1/2, as in panels a and b. Ferrara et al., 2003) . Consistently, GFP-aFOS hardly decayed during the CHX chase (Figure 2b) , suggesting that stabilization of c-Jun in GFP-aFOS cells could be due to heterodimerization with the stable GFP-aFOS protein.
To further investigate the possibility that heterodimerization with a stable partner could have a role in (Oliviero et al., 1992) . First, transfection in FRTL-5
Ki-RAS cells showed that c-Jun GLZ -HA accumulated much less efficiently than did c-Jun-HA. Pulse-chase analyses showed that c-Jun GLZ was less stable than c-Jun-HA (Figure 2c) . Next, we investigated the stability of both c-Jun derivatives in the RAS-inducible cell system. CHX chases showed that the exogenous HA-tagged c-Jun behaved similarly to the endogenous c-Jun, with a half-life increasing from B2 h to 46 h after tamoxifen induction. In contrast, the homodimerizing-only c-Jun GLZ -HA protein was not as dramatically stabilized as c-Jun-HA upon RAS pathway activation (Figure 2d) .
The above results (Figures 1 and 2) indicate that both the MEK/ERK pathway and the interaction of c-Jun with heterodimeric partner(s) are required for RAS-mediated stabilization of c-Jun. Fra-1 is the predominant FOS family member expressed in RAStransformed rat thyroid cells (Talotta et al., 2009) . The formation of c-Jun-Fra-1 heterodimers was strongly suggested by the recovery of both polypeptides in the same fractions, by gel-filtration analysis of total proteins from tamoxifen-induced FRTL-5 ER-RAS cells (Supplementary Figure S4 ). Therefore, to test whether Fra-1 might be the stabilizing dimerization partner of c-Jun, we resorted to different complementary approaches. In the first step, we compared two previously reported FLAG-tagged AP-1-tethered dimers, in which c-Jun is covalently joined either to itself or to Fra-1 by a polypeptide linker (Figure 3a) . These artificial dimers recapitulate the known properties of natural AP-1 dimers (Bakiri et al., 2002) . Upon expression from similar constructs, the pseudoheterodimeric c-Jun/Fra-1-FLAG fusion protein accumulated to a much more elevated level than did the homodimeric c-Jun/c-Jun-FLAG protein in transfected FRTL-5
Ki-RAS cells (Figure 3a) . Accordingly, c-Jun/c-Jun-FLAG was particularly short lived (half-life o1.5 h), whereas c-Jun/ Fra-1-FLAG was much more stable (half-life 44 h) (Figure 3b) . Similar results were obtained by transfecting the two artificial dimers in FRTL-5 ER-RAS cells, in which we also observed that the endogenous tamoxifeninduced Fra-1 showed approximately the same stability as the c-Jun/Fra-1-FLAG fusion (Figure 3c) . Furthermore, in both radioactive and nonradioactive chases, the decreased mobility of Fra-1-containing dimers was likely consequent to the progressively increasing protein phosphorylation.
Although the above data strongly suggested that c-Jun was stabilized upon heterodimerization with Fra-1, we wanted to rule out possible artifacts due to the use of artificial AP-1 dimers in the second step of our study. To achieve this, we first analyzed the effect of Fra-1 on c-Jun stability in various coexpression experiments of wild-type and mutant Fra-1 with Myc-tagged c-Jun derivatives. Further supporting our conclusion, a dimerization-defective c-Jun derivative (Myc-c-JunDLZ) was unaffected by exogenous Fra-1 in uninduced FRTL-5 ER-RAS cells, whereas a wild-type Myc-c-Jun protein was stabilized to some extent when coexpressed with Fra-1 under the same conditions ( Figure 3e ). As stabilization of Myc-c-Jun was moderate in the latter experiment, we considered that phosphorylation-dependent stabilization of Fra-1 might be critical for efficient stabilization of c-Jun. MEK/ERK-dependent phosphorylation of S252 (to a limited extent) and S265 (much more efficiently) was shown to stabilize Fra-1 in HeLa cells (Basbous et al., 2007) . Consistently with these data, exogenously expressed Fra-1 was much less stable in uninduced FRTL-5 ER-RAS cells displaying low MEK/ ERK activity than endogenous Fra-1 in tamoxifentreated FRTL-5 ER-RAS cells (compare Figures 3e and d ) wherein it was found to be phosphorylated on S265 (Figure 3d) . A double Fra-1 phosphomimetic mutant (Fra-1DD), in which S252 and S265 were mutated to aspartic residues, was much more stable than Fra-1 in uninduced FRTL-5 ER-RAS cells. Strengthening the idea that stabilization of c-Jun was dependent on that of Fra-1, Fra-1DD led to stronger stabilization of Myc-c-Jun than wild-type Fra-1 in uninduced FRTL-5 ER-RAS cells and had c-Jun stabilization in RAS transformation F Talotta et al no effect on Myc-c-JunDLZ (Figure 3e ). To test whether the observed heterodimerization-mediated stabilization could be reciprocal, we also investigated the effect of c-Jun on Fra-1 half-life. The results did not show any significant stabilization (Supplementary Figure S5) . The above data suggested that Fra-1-mediated heterodimerization could be at least partially responsible for the observed decrease in c-Jun polyubiquitylation in RAS-transformed cells (Figure 1c) . Therefore, we performed c-Jun ubiquitylation assays in the presence of wild-type and phosphomimetic Fra-1. Coexpression with Fra-1 resulted in a slight decrease in polyubiquitylated c-Jun isoforms, with a further reduction in the presence of phosphomimetic Fra-1 (Figure 3f ). However, these changes were much smaller than those observed in Ki-RAS vs FRTL-5 cells, suggesting that the RAS-dependent decrease in c-Jun polyubiquitylation requires additional mechanisms besides Fra-1-mediated heterodimerization.
In a third step, we tested the effect of Fra-1 downregulation by RNA interference in RAS-expressing FRTL-5
Ki To our knowledge, this is the first report on the role of heterodimerization in the control of c-Jun turnover in neoplastic cells. Our data strongly suggest that Fra-1 inhibits c-Jun breakdown in response to the activation of the RAS/RAF/MEK/ERK pathway. Whether stabilization of c-Jun exclusively relies on heterodimerization with Fra-1 stabilized upon phosphorylation by kinases of the ERK pathway is not yet clear.
The lack of effect of U0126 on c-Jun Ser73 phosphorylation under conditions not affecting c-Jun level suggests that phosphorylations of the N-terminal part of this protein are not implicated in ERK-mediated stabilization, raising the question of the possible role of other c-Jun phosphoacceptor sites. It has been reported that ERK inhibition can antagonize TPA-induced dephosphorylation of c-Jun Thr239 (Morton et al., 2003) . GSK3-mediated phosphorylation of Thr239 generates a docking site for Fbw7, which triggers both ubiquitylation and degradation of c-Jun (Wei et al., 2005) . Remarkably, it has been previously proposed that phosphorylation of another component of the AP-1 complex might induce a conformational change that makes Thr239 more sensitive to dephosphorylation by TPA (Morton et al., 2003) . Therefore, Fra-1 might represent the previously postulated AP-1 component, at least in RAS-transformed thyroid cells. In particular, our findings suggest the possibility that, within the context of a c-Jun/Fra-1 heterodimer, ERK-phosphorylated Fra-1 might interfere with the phosphorylation of c-Jun Thr239 and recruitment of the Fbw7 ubiquitin ligase.
Our data raise the question on whether c-Jun is preferably degraded in its monomeric or its dimeric form. As the Jun:Jun dimers dissociate more rapidly than do the Fos:Jun dimers, it can be speculated that monomeric c-Jun might be more susceptible to ubiquitylation reactions and subsequent proteasomal destruction. Moreover, it will be important to understand whether phosphorylation of Fra-1 increases not only Fra-1 stability but also the interaction time between Fra-1 and c-Jun. Alternatively, one can also speculate that Fra-1 is preferably degraded in its monomeric form and that its stabilization might be the consequence of phosphorylation-dependent increased interaction time with c-Jun when the RAS pathway is active.
Fra-1 is a key regulator of cell motility, invasiveness, growth and survival of tumor cells (Kustikova et al., 1998; Vial et al., 2003; Belguise et al., 2005; Debinski and Gibo, 2005; Casalino et al., 2007) . Given the apparent contradiction between the absence of a bona fide transactivation domain and the oncogenic activity of the protein, it was suggested that Fra-1 activity significantly depends on its heterodimeric partner(s) (Bergers et al., 1995) . Our results highlight a novel function of Fra-1 as a posttranslational regulator of c-Jun stability in RAS transformation. The crosstalk between Fra-1 and c-Jun seems to be reciprocal, as c-Jun has been previously characterized as a transcriptional regulator of Fra-1 in response to RAS and tumor promoters (Casalino et al., 2003; Adiseshaiah et al., 2008) . Therefore, the autoregulatory loop between c-Jun and Fra-1 might represent an important determinant for the increased AP-1 activity and a novel target for therapeutic intervention in tumorigenesis.
